ZFP36L2

Across TCGA pan-cancer cohorts, ZFP36L2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZFP36L2 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher ZFP36L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFP36L2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

KICH, BLCA, and SKCM are the cancer types where ZFP36L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.035	0.904	<.001	30	view →
BLCA	DFS	Median	III,IV	1.000	0.296	.016	18	view →
SKCM	OS	Median	All	0.245	0.781	.008	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	All	0.147	0.700	.002	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZFP36L2–KICH (DFS)

Open the KICH breakdown →